Journal
CLINICS IN LABORATORY MEDICINE
Volume 38, Issue 3, Pages 553-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cll.2018.05.006
Keywords
FDA de novo pathway; Traceable LC-MS/MS method; CDC Vitamin D Standardization Certification Program (VDSCP); 25-Hydroxyvitamin D2; 3-Epi-25-hydroxyvitamin
Categories
Funding
- SCIEX
Ask authors/readers for more resources
Despite great improvement in vitamin D assay standardization, inaccurate recoveries of 25(OH)D-2 remain for immunoassays, and many laboratory developed LC-MS/MS methods do not separate out the 3-epimer interferents. Through the process of obtaining Food and Drug Administration (FDA) clearance, we learned that communication is key. Mass spectrometry-based assays raise different questions of safety and efficacy than the predicate immunoassays, with fewer risks due to increased accuracy. This process required improving our quality management system to support the development and registration of an in vitro diagnostic device. There are similar examples for a number of analytes, requiring expeditious entry of FDA-cleared LC-MS/MS methods into clinical laboratories.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available